Depomed initiates enrollment for second Phase III hot flashes trial
Breeze 1, the first Phase III clinical trial, was initiated in September 2008. Breeze 2 differs from Breeze 1 in its treatment duration, which will be three months
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an investigational therapy intended for adults with uncontrolled gout.